Last reviewed · How we verify

NCT06834594: BOOST

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

Recruiting now Phase 4 Last updated 4 September 2025
What this trial tests

Phase 4 trial testing Micronized progesterone 200 MG in Turner Syndrome in 40 participants. Currently enrolling.

Timeline
31 July 2025
Primary endpoint
30 July 2026
31 July 2026

Quick facts

Lead sponsorChildren's Mercy Hospital Kansas City
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment40
Start date31 July 2025
Primary completion30 July 2026
Estimated completion31 July 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Children's Mercy Hospital Kansas City

Who can join

Adults 12 to 20, female only, with Turner Syndrome or Primary Ovarian Insufficiency (Poi). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Turner Syndrome

Currently open trials in the same condition.

Other Children's Mercy Hospital Kansas City trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06834594.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing